Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 14;226(12):2170–2180. doi: 10.1093/infdis/jiac415

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 4. — Case summaries: injection-phase infections (cases D1–D4). Key events and laboratory results for participants who acquired HIV infection while receiving CAB injections: (A) case D1, (B) case D2, (C) case D3, and (D) case D4. Key features of the figure are as in Figure 2. Viral load values <40 indicate that HIV RNA was detected below the lower limit of quantification. One viral load result was obtained with a single-copy RNA assay (asterisk, case D2). The nonnucleoside reverse transcriptase inhibitor resistance mutation, K103N, is shown in blue text (case D3). Abbreviations: Ag/Ab, antigen/antibody test; BLQ, below limit of quantification; CAB, cabotegravir; DRVc, darunavir/cobicistat; DRVr, darunavir/ritonavir; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; IND, indeterminate; ND, not detected; PEP, postexposure prophylaxis; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Figure 4. — Case summaries: injection-phase infections (cases D1–D4). Key events and laboratory results for participants who acquired HIV infection while receiving CAB injections: (A) case D1, (B) case D2, (C) case D3, and (D) case D4. Key features of the figure are as in Figure 2. Viral load values <40 indicate that HIV RNA was detected below the lower limit of quantification. One viral load result was obtained with a single-copy RNA assay (asterisk, case D2). The nonnucleoside reverse transcriptase inhibitor resistance mutation, K103N, is shown in blue text (case D3). Abbreviations: Ag/Ab, antigen/antibody test; BLQ, below limit of quantification; CAB, cabotegravir; DRVc, darunavir/cobicistat; DRVr, darunavir/ritonavir; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; IND, indeterminate; ND, not detected; PEP, postexposure prophylaxis; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.